“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
There is great interest in the application of ‘artificial intelligence’ (AI) to pharmacovigilance (PV). Although US FDA is broadly exploring the use of AI for PV, we focus on the application of AI to the processing and evaluation of Individual Case Safety Reports (ICSRs) submitted to the FDA Adverse Event Reporting System (FAERS). We describe a general framework for considering the readiness of AI for PV, followed by some examples of the application of AI to ICSR processing and evaluation in industry and FDA. We conclude that AI can usefully be applied to some aspects of ICSR processing and evaluation, but the performance of current AI algorithms requires a ‘human-in-the-loop’ to ensure good quality. We identify outstanding scientific and policy issues to be addressed before the full potential of AI can be exploited for ICSR processing and evaluation, including approaches to quality assurance of ‘human-in-the-loop’ AI systems, large-scale, publicly available training datasets, a well-defined and computable ‘cognitive framework’, a formal sociotechnical framework for applying AI to PV, and development of best practices for applying AI to PV. Practical experience with stepwise implementation of AI for ICSR processing and evaluation will likely provide important lessons that will inform the necessary policy and regulatory framework to facilitate widespread adoption and provide a foundation for further development of AI approaches to other aspects of PV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sittig, D. F., & Singh, H. (2010) · Quality and Safety in Health Care · doi:10.1136/qshc.2010.042085 · Cited by 897 · cited 2×
“Successful implementation of information technology systems requires an understanding of the complex inter-relationships among hardware, software, information content, and the human–computer interface [63].”
BackgroundKreimeyer, K., Foster, M., Pandey, A., Arya, N., Halford, G., Jones, S. F., Forshee, R., Walderhaug, M., & Botsis, T. (2017) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2017.07.012 · Cited by 616
Methods for Causality Assessment of Adverse Drug Reactions: A Systematic Review
Agbabiaka, T. B., Savović, J., & Ernst, E. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00003 · Cited by 366
Cited by
Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Sánchez-Guirales, S. A., Simon, J. A., Tomietto, G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101328 · Cited by 488
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
Cutroneo, P. M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., Moretti, U., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1323057 · Cited by 224
Busch, F., Hoffmann, L., Truhn, D., Palaian, S., Alomar, M., Shpati, K., Makowski, M. R., Bressem, K. K., & Adams, L. C. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15911 · Cited by 80
“10 AI can also expedite the drug discovery and development process, utilizing machine learning models to scrutinize extensive molecular data and pinpoint therapeutic targets.”
BackgroundIntroduction to Drug Safety and Pharmacovigilance
Jose, J., Cox, A. R., & Bate, A. (2024) · Principles and Practice of Pharmacovigilance and Drug Safety · doi:10.1007/978-3-031-51089-2_1 · Cited by 3
Metadata
- Authors
- Ball, R., & Dal Pan, G.
- Venue
- Drug Safety
- Published
- 2022-05
- Volume
- 45
- Issue
- 5
- Pages
- 429-438
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W4280496566
- Cited by
- 95
- References
- 3
- FWCI
- 46.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.